Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 844 across all filing types
Latest filing 2017-10-24 Regulatory Filings
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Malaysian Direct Selling Licence to Propel Bioxyne into MLM 2 pages 538.9KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 25 October 2017 from Bioxyne Limited regarding the receipt of a Malaysian Direct Selling Licence and plans to expand into Multi-Level Marketing in Malaysia. It contains no financial statements, no discussion of financial results, no regulatory certifications, or voting results. It is a business update about licensing and market expansion. The document length is short (2851 characters) and does not contain any report or financial data. This fits best into the category of a general regulatory announcement or business update that does not fit other specific categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2017-10-24 English
Quarterly Activities Report and Appendix 4C 8 pages 783.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Report for the Period Ended 30 September 2017' and contains detailed financial information including cash flow statements, operating activities, investing activities, and financing activities for the quarter. It also includes narrative on company activities during the quarter, such as sales, clinical trials, and office openings. The document references compliance with Listing Rule 4.7B, which pertains to quarterly reporting for entities listed on the ASX. The length of the document (13,002 characters) and the presence of substantive financial data and analysis confirm it is a full quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2018
2017-10-24 English
Appendix 3B 13 pages 731.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including classes of securities, number issued, issue price, purpose, shareholder approvals, and quotation requests. It references ASX listing rules and compliance with securities law. The content is consistent with an official announcement of new share issues and capital changes rather than a full financial report or earnings release. The document length is substantial and contains detailed data about the capital issuance, but it is not a financial report or management discussion. Therefore, the document fits the category of Share Issue/Capital Change (SHA).
2017-10-16 English
Response to ASX Price Query Letter 5 pages 635.1KB
Regulatory Filings Classification · 95% confidence The document is a letter from Bioxyne Limited responding to a price query from ASX Compliance regarding unusual trading activity in the company's securities. It references Listing Rules 3.1 and 3.1A about continuous disclosure obligations and confirms that the company is in compliance with these rules. The document is a formal response to a regulatory inquiry rather than a financial report or announcement of financial results. It does not contain financial statements, earnings data, or detailed management discussion. It is also not a report publication announcement but a regulatory compliance communication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2017-10-15 English
Appendix 3B 13 pages 728.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class and number of securities issued, issue price, purpose of the issue, shareholder approvals, and compliance with ASX listing rules. It also includes a calculation of placement capacity under ASX rules 7.1 and 7.1A, which are related to capital raising and share issuance limits. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding the issuance of new shares and options by Bioxyne Limited. It is not a financial report, earnings release, or management discussion, but rather a regulatory filing specifically about capital raising and share issuance. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and content confirm it is the announcement itself, not just a brief notice or report publication announcement.
2017-10-11 English
Annual Report to shareholders 59 pages 1.5MB
Annual Report Classification · 100% confidence The document is titled 'Financial Report for the Year Ended 30 June 2017' and includes detailed sections such as Chairman's Letter, Directors' Report, Auditor’s Independence Declaration, full financial statements (Profit or Loss, Financial Position, Changes in Equity, Cash Flows), Notes to Financial Statements, Directors' Declaration, Independent Auditor's Report, and Corporate Governance Statement. The content covers comprehensive financial performance and company activities for the full fiscal year ending June 30, 2017. The length is substantial (15,000 characters) and contains actual financial data and analysis, not just an announcement or summary. This matches the definition of an Annual Report (10-K). FY 2017
2017-09-24 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.